Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas Pharma’s Phase IV study showed that Lexiscan (regadenoson) injection was comparable to placebo in causing more than 15% decrease in forced expiratory volume in one second (FEV1) in subjects with asthma or chronic obstructive pulmonary disease (COPD) who are likely candidates for myocardial perfusion imaging (MPI) studies.
Subscribe to our email newsletter
Lexiscan is an A2A adenosine receptor agonist approved for use as a pharmacologic stress agent in radionuclide MPI in patients unable to undergo adequate exercise stress.
Lexiscan was designed to produce coronary vasodilation and increase coronary blood flow by activation of the A2A adenosine receptor.
In the trial, Lexiscan was found to be not significantly different from placebo in causing more than 15% decrease in FEV1 in patients with asthma or COPD.
Additionally, the change in FEV1 was not affected by baseline disease severity for either the asthma or the COPD subject groups.
The multicenter, randomised, double-blind, placebo-controlled study evaluated patients 18 years of age and older to determine the safety and tolerability of Regadenoson in subjects with asthma or stable COPD.